280 related articles for article (PubMed ID: 14688079)
1. Immunotherapy of Trypanosoma cruzi infection with DNA vaccines in mice.
Dumonteil E; Escobedo-Ortegon J; Reyes-Rodriguez N; Arjona-Torres A; Ramirez-Sierra MJ
Infect Immun; 2004 Jan; 72(1):46-53. PubMed ID: 14688079
[TBL] [Abstract][Full Text] [Related]
2. A therapeutic nanoparticle vaccine against Trypanosoma cruzi in a BALB/c mouse model of Chagas disease.
Barry MA; Wang Q; Jones KM; Heffernan MJ; Buhaya MH; Beaumier CM; Keegan BP; Zhan B; Dumonteil E; Bottazzi ME; Hotez PJ
Hum Vaccin Immunother; 2016 Apr; 12(4):976-87. PubMed ID: 26890466
[TBL] [Abstract][Full Text] [Related]
3. Coadministration of cruzipain and GM-CSF DNAs, a new immunotherapeutic vaccine against Trypanosoma cruzi infection.
Cerny N; Sánchez Alberti A; Bivona AE; De Marzi MC; Frank FM; Cazorla SI; Malchiodi EL
Hum Vaccin Immunother; 2016; 12(2):438-50. PubMed ID: 26312947
[TBL] [Abstract][Full Text] [Related]
4. Expression, purification, immunogenicity, and protective efficacy of a recombinant Tc24 antigen as a vaccine against Trypanosoma cruzi infection in mice.
Martinez-Campos V; Martinez-Vega P; Ramirez-Sierra MJ; Rosado-Vallado M; Seid CA; Hudspeth EM; Wei J; Liu Z; Kwityn C; Hammond M; Ortega-López J; Zhan B; Hotez PJ; Bottazzi ME; Dumonteil E
Vaccine; 2015 Aug; 33(36):4505-12. PubMed ID: 26192358
[TBL] [Abstract][Full Text] [Related]
5. Preventive and therapeutic DNA vaccination partially protect dogs against an infectious challenge with Trypanosoma cruzi.
Quijano-Hernández IA; Castro-Barcena A; Vázquez-Chagoyán JC; Bolio-González ME; Ortega-López J; Dumonteil E
Vaccine; 2013 Apr; 31(18):2246-52. PubMed ID: 23499599
[TBL] [Abstract][Full Text] [Related]
6. Novel protective antigens expressed by Trypanosoma cruzi amastigotes provide immunity to mice highly susceptible to Chagas' disease.
Silveira EL; Claser C; Haolla FA; Zanella LG; Rodrigues MM
Clin Vaccine Immunol; 2008 Aug; 15(8):1292-300. PubMed ID: 18579696
[TBL] [Abstract][Full Text] [Related]
7. Comparative evaluation of therapeutic DNA vaccines against Trypanosoma cruzi in mice.
Sanchez-Burgos G; Mezquita-Vega RG; Escobedo-Ortegon J; Ramirez-Sierra MJ; Arjona-Torres A; Ouaissi A; Rodrigues MM; Dumonteil E
FEMS Immunol Med Microbiol; 2007 Aug; 50(3):333-41. PubMed ID: 17521394
[TBL] [Abstract][Full Text] [Related]
8. Previously unrecognized vaccine candidates control Trypanosoma cruzi infection and immunopathology in mice.
Bhatia V; Garg NJ
Clin Vaccine Immunol; 2008 Aug; 15(8):1158-64. PubMed ID: 18550728
[TBL] [Abstract][Full Text] [Related]
9. Production of recombinant TSA-1 and evaluation of its potential for the immuno-therapeutic control of Trypanosoma cruzi infection in mice.
de la Cruz JJ; Villanueva-Lizama L; Dzul-Huchim V; Ramírez-Sierra MJ; Martinez-Vega P; Rosado-Vallado M; Ortega-Lopez J; Flores-Pucheta CI; Gillespie P; Zhan B; Bottazzi ME; Hotez PJ; Dumonteil E
Hum Vaccin Immunother; 2019; 15(1):210-219. PubMed ID: 30192702
[TBL] [Abstract][Full Text] [Related]
10. Cruzipain and Its Physiological Inhibitor, Chagasin, as a DNA-Based Therapeutic Vaccine Against
Cerny N; Bivona AE; Sanchez Alberti A; Trinitario SN; Morales C; Cardoso Landaburu A; Cazorla SI; Malchiodi EL
Front Immunol; 2020; 11():565142. PubMed ID: 33162979
[TBL] [Abstract][Full Text] [Related]
11. Oral multicomponent DNA vaccine delivered by attenuated Salmonella elicited immunoprotection against American trypanosomiasis.
Cazorla SI; Matos MN; Cerny N; Ramirez C; Alberti AS; Bivona AE; Morales C; Guzmán CA; Malchiodi EL
J Infect Dis; 2015 Mar; 211(5):698-707. PubMed ID: 25160983
[TBL] [Abstract][Full Text] [Related]
12. Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection.
Garg N; Tarleton RL
Infect Immun; 2002 Oct; 70(10):5547-55. PubMed ID: 12228281
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with trypomastigote surface antigen 1-encoding plasmid DNA confers protection against lethal Trypanosoma cruzi infection.
Wizel B; Garg N; Tarleton RL
Infect Immun; 1998 Nov; 66(11):5073-81. PubMed ID: 9784506
[TBL] [Abstract][Full Text] [Related]
14. Trypanosoma cruzi 80 kDa prolyl oligopeptidase (Tc80) as a novel immunogen for Chagas disease vaccine.
Bivona AE; Sánchez Alberti A; Matos MN; Cerny N; Cardoso AC; Morales C; González G; Cazorla SI; Malchiodi EL
PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006384. PubMed ID: 29601585
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic efficacy of TcVac2 against Trypanosoma cruzi in mice.
Gupta S; Garg NJ
PLoS Negl Trop Dis; 2010 Aug; 4(8):e797. PubMed ID: 20706586
[TBL] [Abstract][Full Text] [Related]
16. A therapeutic vaccine prototype induces protective immunity and reduces cardiac fibrosis in a mouse model of chronic Trypanosoma cruzi infection.
Barry MA; Versteeg L; Wang Q; Pollet J; Zhan B; Gusovsky F; Bottazzi ME; Hotez PJ; Jones KM
PLoS Negl Trop Dis; 2019 May; 13(5):e0007413. PubMed ID: 31145733
[TBL] [Abstract][Full Text] [Related]
17. Immune protection against Trypanosoma cruzi induced by TcVac4 in a canine model.
Aparicio-Burgos JE; Zepeda-Escobar JA; de Oca-Jimenez RM; Estrada-Franco JG; Barbabosa-Pliego A; Ochoa-García L; Alejandre-Aguilar R; Rivas N; Peñuelas-Rivas G; Val-Arreola M; Gupta S; Salazar-García F; Garg NJ; Vázquez-Chagoyán JC
PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003625. PubMed ID: 25853654
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Efficacy of a Subunit Vaccine in Controlling Chronic Trypanosoma cruzi Infection and Chagas Disease Is Enhanced by Glutathione Peroxidase Over-Expression.
Gupta S; Smith C; Auclair S; Delgadillo Ade J; Garg NJ
PLoS One; 2015; 10(6):e0130562. PubMed ID: 26075398
[TBL] [Abstract][Full Text] [Related]
19. TcVac1 vaccine delivery by intradermal electroporation enhances vaccine induced immune protection against Trypanosoma cruzi infection in mice.
Hegazy-Hassan W; Zepeda-Escobar JA; Ochoa-García L; Contreras-Ortíz JME; Tenorio-Borroto E; Barbabosa-Pliego A; Aparicio-Burgos JE; Oros-Pantoja R; Rivas-Santiago B; Díaz-Albiter H; Garg NJ; Vázquez-Chagoyán JC
Vaccine; 2019 Jan; 37(2):248-257. PubMed ID: 30497833
[TBL] [Abstract][Full Text] [Related]
20. Delivery of antigenic candidates by a DNA/MVA heterologous approach elicits effector CD8(+)T cell mediated immunity against Trypanosoma cruzi.
Gupta S; Garg NJ
Vaccine; 2012 Nov; 30(50):7179-86. PubMed ID: 23079191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
